Regeneron Pharmaceuticals (REGN) stock

Medicines for disease , market cap $93B

Medicines for disease

Worth $93B

$916.06

-0.42%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Excellent

In its industry

#19of 281

Biotech

Checks firing

7of 14

Trending up

From 52-week high

-7.6%

under its best in a year

REGN's Quality Score rose 2 points on Tue, Nov 10, to 16. It closed near its high of the day (3 chart checks started).

Follow REGN's trial news. Pro members can get an alert when Regeneron Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when REGN files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextNov 2026“…interim results at the American Association for the Study of Liver Diseases (AASLD) Meeting in November 2026…”Trial data · SEC filing · Oct 30

Why REGN rose 13% since Oct 28

Up 13% from Oct 28 to Nov 10.

Regeneron Pharmaceuticals rose 12.6% from Oct 28 to Nov 10. It rose 13% on Oct 30 alone, the day of its results.

Sources: Price history, Nov 10, 2026; SEC filing, Oct 30, 2026

1 more reason, free with an account →3 more reasons why REGN rose 13% since Oct 28, from its filings, with the timeline and its peers, for Pro members.

Key facts on REGN

Key facts on REGN
The company	Sales growth sped up 3 quarters in a row 1% to 19%
Latest filing	10-Q, Oct 30 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

1 more reason behind REGN's 16, free with an account →6 more reasons behind REGN's 16, for Pro members.

REGN in the news

Mon Nov 2Regeneron Pharma (REGN) PT Raised to $1,030 at BofA Securities streetinsider and 1 more REGN closed +3.6% that day.

What's next

Tue Nov 17: Jefferies 17th Annual London Global…Investor conference · date confirmed.

6 more dates ahead: conferences and dividend dates, for Pro members.

REGN catalysts

Coming up

After its last 4 reports it closed +3.1% on average, higher 2 of 4 times.

3 more coming up and 22 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for REGN

Next step the company has named

Nov 2026“…plans to present interim results at the American Association for the Study of Liver Diseases (AASLD) Meeting in November 2026 and to initiate a Phase 3 study in metabolic…”Trial data · SEC filing · Oct 30

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: ROXI-APEXPhase 3 · Recruiting · 2,000 people · main data estimated Feb 20, 2027 · NCT07015905

112 more trials, 5 with data due this year, 45 drugs past Phase 1 and 26 filings, for Pro members.

Dilution on the horizon

Shelf registration (S-3ASR, filed Oct 31, 2024)

For Pro members: the amounts, and the share count against a year ago.

Insiders

SVP Controller Jason Pitofsky sold 4,062 shares on Nov 4. 20 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Leonard Schleifer buys or sells

For Pro members: every trade, and Leonard Schleifer’s 2 filings and quotes.

Get an alert when REGN files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why REGN scores 16

Excellentfor quality, not price, 7 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. REGN scores 16 today, against a median of 9.5 over its last 20 recorded sessions.

+7Chart checks 7 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Run-up adds
Size adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Persistence adds
News adds
Insider trades subtracts

No effect today: Dilution, Volatility, and Cash flow.

What every line is worth, and the reason behind it, on REGN and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:56 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when REGN's Quality Score turns up

A free account. No card.

How REGN ranks in Biotech

REGN is #19 of 281 by Quality Score.

How REGN ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	RCKTRocket Pharmaceuticals		Open for its score
	RCUSArcus Biosciences		Open for its score
	RGENRepligen		Open for its score
	RGNXREGENXBIO		Open for its score
19	REGNRegeneron Pharmaceuticals	7/14	16

Share count against a year before: REGN -1.8%, ALNY +1.8%, BMY +0.3%, MRK -1.1%.

When does REGN report earnings, and what happens after?

Expected to report Thu Jan 28, before the open (in 79 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What REGN reported on Oct 30, 2026

The quarter

A profit of $18.45 a share, from $13.62.

“Sanofi collaboration revenue increased in the third quarter of 2026, compared to the third quarter of 2025, due to an increase in the Company's share of profits from the commercialization of antibodies, which were $2.575 billion and $1.456 billion in the third quarter of 2026 and 2025, respectively.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Collaboration Revenueup 52%	$3B53%	$2.5B51%	$2B48%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 30)

5 more lines, for Pro members.

The outlook

No outlook figures read from this release.

In the company's words

“Libtayo U.S. net product sales increased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to higher sales volumes driven by increased demand.”

From its results filing (SEC filing · Oct 30)

The numbers

Market value: $93B; today
Sales: $17B; up 18.6% on the year
Free cash flow: $3.8B; last 12 months

Sales grew 11% a year over 5 years, fiscal 2020 to 2025.

Pays $3.76 a share a year.

5 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on REGN: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-6.2%+6.2%+13.3%

Apr 29Jul 30Oct 30

Reported	When	Gap	Reaction	5 days
Oct 30, 2026Before open	Before open	+6.2%	+13.3%	+10.3%
Jul 30, 2026Before open	Before open	+0.9%	+6.2%	+10.5%
Apr 29, 2026Before open	Before open	-3.6%	-6.2%	-4.0%

REGN closed higher after 2 of its last 4 reports.

All 4 reports, and REGN's Quality Score going into each

REGN sales and profit by year

Sales and profit by year

Sales grew in six of the last seven years, to $14B in 2025. It made a profit in each of the eight years.

REGN has 7 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on REGN, and all 14 on every stock.Get in free →

REGN RSI today: 64.3, above its 50-day and 200-day averages

Not scored

RSI 64.3, MACD above signal, above both averages. Not scored.13 readings

The deep dive on REGN

What it does and how it makes money4 findingsCollaboration Revenue made up 51% of its revenue in fiscal 2025 ($7.33B of $14.3B), against 43% in fiscal 2024; product sales 44%.SEC filing · Feb 4, 2026"In October 2025, the Munich Regional Court issued a decision that found that Formycon's aflibercept biosimilar product infringes the '691 Patent and granted the Company's motion for a permanent injunction …" (10-K for fiscal 2025)SEC filing · Feb 4, 2026
Where it stands4 findingsFor Pro members4 findings on where REGN stands: its cash, debt, and share count, for Pro members
What changed in its filings7 findings"On October 9, 2026, the court denied the Company's motion to dismiss as to the plaintiff's breach of fiduciary duty claim, but granted it as to the unjust enrichment and corporate waste claims." (10-Q for the quarter to Sep 30, 2026)SEC filing · Oct 30, 2026A new heading in its "Risk Factors" this year: "We face risks associated with tariffs and other trade restrictions, which may have a material adverse impact on our results of operations and financial condition." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 4, 2026, against the one of Feb 5, 2025One customer made up 50% of its revenue in fiscal 2025, the same as in fiscal 2024; another made up 27%, up from 24% in fiscal 2024.SEC filing · Feb 4, 2026
Who holds and trades it5 findingsFor Pro members5 findings on who holds and trades REGN, for Pro members
Against its closest peers3 peersShare count against a year before: REGN -1.8%, ALNY +1.8%, BMY +0.3%, MRK -1.1%.

15 more findings on REGN, each with its source, for Pro members.

REGN share count over time

Shares: 1.8% fewer than a year ago (to Sep 30).

Shares of REGN outstanding, as filed
Shares outstanding	As of
94M	Jul 13, 2012
93M	Apr 11, 2012
91.8M	Feb 10, 2012
90.5M	Oct 19, 2011

Offerings, shelves, and splits of REGN, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Oct 31, 2024

REGN insider trades

5 insiders sold $43.3M across 27 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellJason Pitofsky$1.1MSVP Controllerat $942.31 on Nov 4, filed Nov 6

SellJason PitofskySVP Controller$1.1Mat $942.31 on Nov 4, filed Nov 6

All 27 insider filings on REGN from the last six months, for Pro members.

All REGN insider trades

REGN trades by Congress and the executive branch

18 trades disclosed in the last six months. The newest:

BuyRo Khanna$1K to $15KHousetraded Oct 7, disclosed Nov 5(29 days later)

BuyRo KhannaHouse$1K to $15Ktraded Oct 7, disclosed Nov 5(29 days later)

All 18 trades on REGN disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

REGN's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Leonard S. SchleiferBd. Co-Chair, President & CEO · no trades on file
George YancopoulosBd. Co-Chair, President & CSO · no trades on file
Christopher R. FenimoreEVP Finance CFO · no trades on file
Jason PitofskySVP Controller · 9 trades
Marion McCourtEVP Commercial · 3 trades
Joseph J. LarosaEVP General Counsel and Secret · 2 trades
Andrew J. MurphyCo-Chief Scientific Officer · 1 trade
Daniel P. Van PlewEVP & General Mgr, Industrial · no trades on file

11 more officers and directors file at REGN.

See insider trades by person

Which ETFs hold REGN?

In ETFs: REGN is 1.5% of JEPI, 0.6% of JEPQ, and 0.5% of QQQI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

15,410 employeesTarrytown, NYregeneron.com

What Regeneron Pharmaceuticals says it competes with

“We face substantial competition from pharmaceutical and biotechnology companies.”

From its annual report, SEC filing · Feb 4, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on REGN and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move REGN's score: 6 things
5 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayNov 5Ro Khanna bought REGN$1K to $15K, disclosed Nov 5

Alerts are optional.

See REGN's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: REGN's Quality Score is 16 (Excellent), #19 of 281 in Biotech. Insiders sold $43.3M in the last 6 months (Form 4).

What does REGN's Quality Score say?

REGN scores 16 today, which Breakaway calls Excellent. It is #19 of 281 in Biotech by Quality Score, with 7 of 14 chart checks firing. Up 13% from Oct 28 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is REGN's Quality Score?

REGN scores 16 today, which Breakaway calls Excellent (15 to 19). That is #19 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind REGN's 16.

Are insiders buying REGN?

5 insiders sold $43.3M across 27 filings in the last 6 months. No open-⁠market buys on record. The newest is Jason Pitofsky, SVP Controller, who sold $1.1M on Nov 4. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.